Categories: Media Partners

9th Annual Clinical Trials Summit 2018

 “A critical guide for successfully conducting clinical trials”

22nd May 2018, Kohinoor Continental Hotel, Mumbai, India

Virtue Insight welcomes you to attend the 9th Annual Clinical Trials Summit 2018, which is going to be held in on 22nd May 2018 at Kohinoor Continental Hotel, Mumbai, India. 9th Annual Clinical Trials Summit 2018 anticipates participants around the globe with thought provoking Keynote lectures, Oral Presentations and Poster Presentations. The main theme of the conference is to positively learn and educate about clinical trials is essential, if only to counter more negative perceptions.

KEY SPEAKERS:

  • OMPRAKASH S. SADHWANI, Joint Commissioner (Nashik Division), Food and Drugs Administration (M.S.)
  • BANGARURAJAN, Joint Drugs Controller (INDIA), CDSCO (HQ)
  • MAYUR PARMAR, Deputy Collector, Government of Gujarat
  • NILIMA A. KSHIRSAGAR, National Chair Clinical Pharmacology, ICMR Govt. of India
  • MUZAFFAR AHMAD, Member Strategic Advisory Board on Health Millenium Alliance (Govt of India) and Member Council of India
  • DEVEN V PARMAR, Vice President & Head Clinical R&D, Cadila Healthcare
  • ARUN BHATT, Consultant – Clinical Research & Development
  • SANDESH SAWANT, Director and Head Clinical Trials, Cipla
  • CHIRAG TRIVEDI, Director & Head of Clinical Study Unit, Sanofi-aventis
  • DILIP PAWAR, Independent Clinical Consultant
  • SHIRAZ KANDAWALLA, Associate Director – Regulatory Affairs, Abbott
  • BINDU AJIT, Program Director, Biocon Academy
  • AMMAR RAZA, Country Medical Director & Chief Medical Office, Allergan
  • KEDAR SUVARNAPATHAKI, Head – Regulatory Affairs & IP, Boehringer Ingelheim
  • MILIND ANTANI, Partner In-Charge – Pharma LifeSciences, Nishith Desai Associates
  • PRAVIN GHADGE, Head of Clinical Research Services, Reliance Life Sciences
  • SIDDHARTH DESHPANDE, Assistant Professor Department of Clinical Pharmacology, KEM Hospital
  • AGAM SHAH, Head Clinical Operations, Wockhardt
  • JYOTSNA PATWARDHAN, Head Development QA, Novartis
  • CHIRAG TELI, Head of Medical Services, Alkem Laboratories
  • AMEY MANE, General Manager – Medical Affairs, Janssen India
  • SUJAY KULKARNI, Senior Manager – Clinical Research and Pharmacovigilance, GSK
  • RANJIT BARSHIKAR, QbD / CGMP Consulting, Member Editorial Board Journal of Generic Medicines, England
  • PRANJAL BORDOLOI, AVP – Medical Affairs and Pharmacovigilance, Veeda Clinical Research
  • PRASHANT BODHE, Director, CliniSearch

KEY THEMES DISCUSSED:

  • Current challenges and regulations for clinical trials in India
  • Having a positive impact on overall market to globalize trials and growth in new product development in emerging countries
  • Formulating a risk-based inspection plan for advanced clinical trials
  • New tools and technologies for data capture for clinical trials
  • Developing effective partnerships and vendor relationships
  • Necessary strategies to implement the maximize value of the collaboration.
  • Patient and clinical site centricity: Optimising the end users, patients and the clinical sites
  • Encouraging data analytics for next-generation clinical trials
  • EHR (Electronic Health Records) for clinical research facility
  • Recent guidelines issued by FDA on the use of EHR data
  • Major roles of clinical pharmacology in drug discovery and development
  • New clinical trials rules and its impact
  • Current requirements of Indian Clinical Trial Application (CTA) and how this will change with the new clinical trial regulation
  • Regulatory considerations in India and south-east Asia
  • Be part of a major networking opportunity

WHO SHOULD ATTEND:

CEO’s, CTO’s, CIO’s, Presidents, Vice Presidents, Directors Heads & Managers of:

Clinical Research & Development, Clinical Research Services, Clinical Operations, Clinical Data Management, Clinical IT, Clinical Trials, Medical Affairs, Regulatory Affairs, Compliance, Quality control / Assurance/GCP, Clinical Study Design, Safety Surveillance, Subject Recruitment, E-Clinical Systems

CONFERENCE REGISTRATION:

Email- kavitha@virtueinsight.co.in  Or Call- +91 44 24762472

  • Standard Price– 1 or 2 Delegates – (INR 7,000 + GST (18%) per delegate)
  • Group Discounts – 3 or 4 Delegates – (INR 6,500 + GST (18%) per delegate)
  • Group Discounts – 5 and above Delegates – (INR 6,000 + GST (18%) per delegate)
  • Spot Registration on the day of the Conference – 1 Day Conference – (INR 8,000 + GST (18%) per delegate)
  • Conference Sponsor & Exhibition Stall( Booth) or a paid Speaker Slot are also available.

Get more from the event, with a broader scope bringing the whole communications value chain together. Enjoy and make the best out of our dedicated networking time, meet the leading international vendors showcasing the products of tomorrow in the co-located exhibition. Expand your knowledge of the latest business models and strategies in the high-level conference.

http://www.virtueinsight.com/pharma/9th-Annual-Clinical-Trials-Summit-2018/

The Pharma Times News Bureau

Share
Published by
The Pharma Times News Bureau

Recent Posts

Bayer Introduces Bepanthen in India as New Survey Reveals Dry Skin Affects 1 in 2 Indians

·        World's no.1 skincare brand Bepanthen* launches in India, as a solution to tackle India's widespread dry skin…

8 hours ago

Lung Cancer in India: Understanding Risk Factors and the Importance of Early Detection

By Dr. Pavan Yadav, Lead Consultant - Interventional Pulmonology & Lung Transplantation, Aster RV Hospital.…

1 day ago

10 Winter Skin Care Tips Dermatologists Swear By

Dr. Priyanka Kuri, Consultant - Dermatology, Aster Whitefield Hospital, Bengaluru  Winter weather brings a host…

4 days ago

Fighting Viral Hepatitis in India: Prevention, Risks, and the Path to Better Health

By Dr. Naveen Ganjoo, Senior Consultant - Hepatology & Integrated Liver Care, Aster RV Hospital…

5 days ago

Hon’ble Prime Minister Shri Narendra Modi Inaugurates LyfiusPharma’s Flagship Penicillin-G Facility at Kakinada, Andhra Pradesh

Under the Production Linked Incentive(PLI)scheme, Lyfius Pharma Private Limited(LyfiusPharma) invested ₹2,500 crores in Penicillin-G( Pen-G)facility…

6 days ago